↓ Skip to main content

Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation

Overview of attention for article published in Pulmonary Pharmacology & Therapeutics, July 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation
Published in
Pulmonary Pharmacology & Therapeutics, July 2016
DOI 10.1016/j.pupt.2016.07.005
Pubmed ID
Authors

Ibrahim Sulaiman, Jonathan Chee Woei Lim, Liong Soo, Johnson Stanslas

Abstract

Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe asthma necessitate the development of better medications. Numerous drug targets with inherent airway smooth muscle tone modulatory role have been identified for asthma therapy. This article reviews the latest understanding of underlying molecular aetiology of asthma towards design and development of better antiasthma drugs. New drug candidates with their putative targets that have shown promising results in the preclinical and/or clinical trials are summarised. Examples of these interventions include restoration of Th1/Th2 balance by the use of newly developed immunomodulators such as toll-like receptor-9 activators (CYT003-QbG10 and QAX-935). Clinical trials revealed the safety and effectiveness of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists such as OC0000459, BI-671800 and ARRY-502 in the restoration of Th1/Th2 balance. Regulation of cytokine activity by the use of newly developed biologics such as benralizumab, reslizumab, mepolizumab, lebrikizumab, tralokinumab, dupilumab and brodalumab are at the stage of clinical development. Transcription factors are potential targets for asthma therapy, for example SB010, a GATA-3 DNAzyme is at its early stage of clinical trial. Other candidates such as inhibitors of Rho kinases (Fasudil and Y-27632), phosphodiesterase inhibitors (GSK256066, CHF 6001, roflumilast, RPL 554) and proteinase of activated receptor-2 (ENMD-1068) are also discussed. Preclinical results of blockade of calcium sensing receptor by the use of calcilytics such as calcitriol abrogates cardinal signs of asthma. Nevertheless, successful translation of promising preclinical data into clinically viable interventions remains a major challenge to the development of novel anti-asthmatics.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 79 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 15%
Researcher 10 13%
Student > Bachelor 9 11%
Student > Doctoral Student 6 8%
Other 5 6%
Other 14 18%
Unknown 24 30%
Readers by discipline Count As %
Medicine and Dentistry 22 28%
Agricultural and Biological Sciences 10 13%
Pharmacology, Toxicology and Pharmaceutical Science 8 10%
Biochemistry, Genetics and Molecular Biology 5 6%
Nursing and Health Professions 3 4%
Other 8 10%
Unknown 24 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2020.
All research outputs
#16,722,190
of 25,374,917 outputs
Outputs from Pulmonary Pharmacology & Therapeutics
#519
of 828 outputs
Outputs of similar age
#239,220
of 378,455 outputs
Outputs of similar age from Pulmonary Pharmacology & Therapeutics
#6
of 17 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 828 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,455 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.